Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (FASCINATE-2)

NCT04906421 is registered in ClinicalTrials.gov with Sagimet Biosciences Inc. as lead sponsor.

NCT NCT04906421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04906421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (FASCINATE-2)
Lead sponsor
Sagimet Biosciences Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 12, 2021
Completion date
October 2, 2023
Enrollment
168 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

metabolic dysfunction-assocated steatohepatitis/ nonalcoholic fatty liver disease